Barry T Rouse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6620391/publications.pdf

Version: 2024-02-01

233 papers

12,245 citations

58 h-index 98 g-index

405 all docs 405 docs citations

405 times ranked 11829 citing authors

#	Article	IF	CITATIONS
1	Controlling the Burden of COVID-19 by Manipulating Host Metabolism. Viral Immunology, 2022, 35, 24-32.	0.6	7
2	Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy. Viruses, 2022, 14, 862.	1.5	4
3	Supplementing the Diet with Sodium Propionate Suppresses the Severity of Viral Immuno-inflammatory Lesions. Journal of Virology, 2021, 95, .	1.5	22
4	Climate change: how it impacts the emergence, transmission, resistance and consequences of viral infections in animals and plants. Critical Reviews in Microbiology, 2021, 47, 307-322.	2.7	11
5	Could targeting immunometabolism be a way to control the burden of COVID-19 infection?. Microbes and Infection, 2021, 23, 104780.	1.0	9
6	Inhibiting Glucose Metabolism Results in Herpes Simplex Encephalitis. Journal of Immunology, 2021, 207, 1824-1835.	0.4	9
7	COVID-19: disease, or no disease? - that is the question. It's the dose stupid!. Microbes and Infection, 2021, 23, 104779.	1.0	7
8	Modulating glutamine metabolism to control viral immuno-inflammatory lesions. Cellular Immunology, 2021, 370, 104450.	1.4	10
9	Did Climate Change Influence the Emergence, Transmission, and Expression of the COVID-19 Pandemic?. Frontiers in Medicine, 2021, 8, 769208.	1.2	17
10	Does the hygiene hypothesis apply to COVID-19 susceptibility?. Microbes and Infection, 2020, 22, 400-402.	1.0	21
11	Determinants of Tissue-Specific Metabolic Adaptation of T Cells. Cell Metabolism, 2020, 32, 908-919.	7. 2	27
12	Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. Frontiers in Immunology, 2020, 11, 581076.	2.2	6
13	Host-Directed Antiviral Therapy. Clinical Microbiology Reviews, 2020, 33, .	5.7	99
14	Virus Infections and Host Metabolismâ€"Can We Manage the Interactions?. Frontiers in Immunology, 2020, 11, 594963.	2.2	69
15	Host Defenses to Viruses. , 2019, , 365-374.e1.		5
16	Factors Affecting the Tissue Damaging Consequences of Viral Infections. Frontiers in Microbiology, 2019, 10, 2314.	1.5	16
17	The Role of T Cells in Herpes Stromal Keratitis. Frontiers in Immunology, 2019, 10, 512.	2.2	39
18	Gal power: the diverse roles of galectins in regulating viral infections. Journal of General Virology, 2019, 100, 333-349.	1.3	22

#	Article	IF	Citations
19	Are miRNAs critical determinants in herpes simplex virus pathogenesis?. Microbes and Infection, 2018, 20, 461-465.	1.0	18
20	Application of our understanding of pathogenesis of herpetic stromal keratitis for novel therapy. Microbes and Infection, 2018, 20, 526-530.	1.0	18
21	How host metabolism impacts on virus pathogenesis. Current Opinion in Virology, 2018, 28, 37-42.	2.6	15
22	On the role of retinoic acid in virus induced inflammatory response in cornea. Microbes and Infection, 2018, 20, 337-345.	1.0	21
23	Virological and Immunological Outcomes of Coinfections. Clinical Microbiology Reviews, 2018, 31, .	5.7	147
24	Role of IL-18 induced Amphiregulin expression on virus induced ocular lesions. Mucosal Immunology, 2018, 11, 1705-1715.	2.7	15
25	Herpesviruses: Harmonious Pathogens but Relevant Cofactors in Other Diseases?. Frontiers in Cellular and Infection Microbiology, 2018, 8, 177.	1.8	97
26	Hexokinase II may be dispensable for CD4 T cell responses against a virus infection. PLoS ONE, 2018, 13, e0191533.	1.1	9
27	Azacytidine Treatment Inhibits the Progression of Herpes Stromal Keratitis by Enhancing Regulatory T Cell Function. Journal of Virology, 2017, 91, .	1.5	28
28	Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology. Journal of Leukocyte Biology, 2017, 102, 1159-1171.	1.5	48
29	miR-31: a key player in CD8 T-cell exhaustion. Cellular and Molecular Immunology, 2017, 14, 954-956.	4.8	4
30	Manipulating Glucose Metabolism during Different Stages of Viral Pathogenesis Can Have either Detrimental or Beneficial Effects. Journal of Immunology, 2017, 199, 1748-1761.	0.4	36
31	The Plasticity and Stability of Regulatory T Cells during Viral-Induced Inflammatory Lesions. Journal of Immunology, 2017, 199, 1342-1352.	0.4	44
32	DNA Vaccines – A Modern Gimmick or a Boon to Vaccinology?. Critical Reviews in Immunology, 2017, 37, 483-498.	1.0	5
33	Interplay of Regulatory T Cell and Th17 Cells during Infectious Diseases in Humans and Animals. Frontiers in Immunology, 2017, 8, 341.	2.2	74
34	IL-2 complex treatment amplifies CD8+ T cell mediated immunity following herpes simplex virus-1 infection. Microbes and Infection, 2016, 18, 735-746.	1.0	8
35	The inflammasome NLRP3 plays a protective role against a viral immunopathological lesion. Journal of Leukocyte Biology, 2016, 99, 647-657.	1.5	37
36	Some vexations that challenge viral immunology. F1000Research, 2016, 5, 1015.	0.8	1

#	Article	IF	CITATIONS
37	Role of miR-155 in the Pathogenesis of Herpetic Stromal Keratitis. American Journal of Pathology, 2015, 185, 1073-1084.	1.9	46
38	Robo 4 Counteracts Angiogenesis in Herpetic Stromal Keratitis. PLoS ONE, 2015, 10, e0141925.	1.1	14
39	An Approach to Control Relapse of Inflammatory Lesions after Discontinuation of Primary Therapy. PLoS ONE, 2014, 9, e98051.	1.1	5
40	Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection. Microbes and Infection, 2014, 16, 648-660.	1.0	24
41	Critical Role of MicroRNA-155 in Herpes Simplex Encephalitis. Journal of Immunology, 2014, 192, 2734-2743.	0.4	59
42	Advantages of Foxp3 ⁺ regulatory T cell depletion using DEREG mice. Immunity, Inflammation and Disease, 2014, 2, 162-165.	1.3	28
43	Role of regulatory T cells during virus infection. Immunological Reviews, 2013, 255, 182-196.	2.8	195
44	Pathogenesis of herpes stromal keratitis $\hat{a}\in$ A focus on corneal neovascularization. Progress in Retinal and Eye Research, 2013, 33, 1-9.	7.3	90
45	Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways. Microbes and Infection, 2013, 15, 677-687.	1.0	10
46	Neuroprotectin D1 Reduces the Severity of Herpes Simplex Virus–Induced Corneal Immunopathology. , 2013, 54, 6269.		51
47	Potential Function of miRNAs in Herpetic Stromal Keratitis. , 2013, 54, 563.		14
48	Host defenses to viruses. , 2013, , 346-355.		1
49	Galectin-1 Reduces the Severity of Herpes Simplex Virus-Induced Ocular Immunopathological Lesions. Journal of Immunology, 2012, 188, 4631-4643.	0.4	54
50	Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. British Journal of Ophthalmology, 2012, 96, 3-9.	2.1	75
51	On the Role of Regulatory T Cells during Viral-Induced Inflammatory Lesions. Journal of Immunology, 2012, 189, 5924-5933.	0.4	48
52	IL-17A Differentially Regulates Corneal Vascular Endothelial Growth Factor (VEGF)-A and Soluble VEGF Receptor 1 Expression and Promotes Corneal Angiogenesis after Herpes Simplex Virus Infection. Journal of Immunology, 2012, 188, 3434-3446.	0.4	68
53	TNFRSF25 Agonistic Antibody and Galectin-9 Combination Therapy Controls Herpes Simplex Virus-Induced Immunoinflammatory Lesions. Journal of Virology, 2012, 86, 10606-10620.	1.5	33
54	Role of miR-132 in Angiogenesis after Ocular Infection with Herpes Simplex Virus. American Journal of Pathology, 2012, 181, 525-534.	1.9	96

#	Article	IF	Citations
55	Macrophage IL-12p70 Signaling Prevents HSV-1–Induced CNS Autoimmunity Triggered by Autoaggressive CD4+Tregs. , 2011, 52, 2321.		15
56	T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19001-19006.	3.3	89
57	Tregs and infections: on the potential value of modifying their function. Journal of Leukocyte Biology, 2011, 90, 1079-1087.	1.5	23
58	Role of IL-17 and Th17 Cells in Herpes Simplex Virus-Induced Corneal Immunopathology. Journal of Immunology, 2011, 187, 1919-1930.	0.4	133
59	Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1. Journal of Immunology, 2011, 186, 1735-1746.	0.4	125
60	Activation of Endothelial Roundabout Receptor 4 Reduces the Severity of Virus-Induced Keratitis. Journal of Immunology, 2011, 186, 7195-7204.	0.4	16
61	Influence of Galectin-9/Tim-3 Interaction on Herpes Simplex Virus-1 Latency. Journal of Immunology, 2011, 187, 5745-5755.	0.4	48
62	Ocular Neovascularization Caused by Herpes Simplex Virus Type 1 Infection Results from Breakdown of Binding between Vascular Endothelial Growth Factor A and Its Soluble Receptor. Journal of Immunology, 2011, 186, 3653-3665.	0.4	62
63	An Anti-Inflammatory Role of VEGFR2/Src Kinase Inhibitor in Herpes Simplex Virus 1-Induced Immunopathology. Journal of Virology, 2011, 85, 5995-6007.	1.5	27
64	Controlling Viral Immuno-Inflammatory Lesions by Modulating Aryl Hydrocarbon Receptor Signaling. PLoS Pathogens, 2011, 7, e1002427.	2.1	62
65	Immunity and immunopathology to viruses: what decides the outcome?. Nature Reviews Immunology, 2010, 10, 514-526.	10.6	467
66	Herpetic keratitis., 2010,, 91-97.		7
67	Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. Journal of Experimental Medicine, 2010, 207, 2355-2367.	4.2	33
68	Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+ T Cell Response. PLoS Pathogens, 2010, 6, e1000882.	2.1	150
69	Some unmet challenges in the immunology of viral infections. Discovery Medicine, 2010, 10, 363-70.	0.5	6
70	Role of Tim-3/Galectin-9 Inhibitory Interaction in Viral-Induced Immunopathology: Shifting the Balance toward Regulators. Journal of Immunology, 2009, 182, 3191-3201.	0.4	103
71	Control of viral immunoinflammatory lesions by manipulating CD200:CD200 receptor interaction. Clinical Immunology, 2009, 131, 31-40.	1.4	13
72	Enhanced viral immunoinflammatory lesions in mice lacking IL-23 responses. Microbes and Infection, 2008, 10, 302-312.	1.0	26

#	Article	IF	CITATIONS
73	Homeostatic expansion of CD4+ T cells upregulates VLA-4 and exacerbates HSV-induced corneal immunopathology. Microbes and Infection, 2008, 10, 1192-1200.	1.0	3
74	Immune responses to viruses. , 2008, , 421-431.		32
75	An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus. Hum Vaccin, 2008, 4, 360-364.	2.4	8
76	IL-10 and Natural Regulatory T Cells: Two Independent Anti-Inflammatory Mechanisms in Herpes Simplex Virus-Induced Ocular Immunopathology. Journal of Immunology, 2008, 180, 6297-6306.	0.4	55
77	Anti-Inflammatory Effects of FTY720 against Viral-Induced Immunopathology: Role of Drug-Induced Conversion of T Cells to Become Foxp3+ Regulators. Journal of Immunology, 2008, 180, 7636-7647.	0.4	65
78	Natural Killer Cells as Novel Helpers in Anti-Herpes Simplex Virus Immune Response. Journal of Virology, 2008, 82, 10820-10831.	1.5	55
79	In Vitro-Generated Antigen-Specific CD4 ⁺ CD25 ⁺ Foxp3 ⁺ Regulatory T Cells Control the Severity of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions. Journal of Virology, 2008, 82, 6838-6851.	1.5	68
80	Non-mitogenic Anti-CD3F(ab′)2Monoclonal Antibody: A Novel Approach to Control Herpetic Stromal Keratitis., 2008, 49, 5425.		3
81	Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. Journal of Virology, 2007, 81, 2545-2553.	1.5	431
82	Role of Stat4-Mediated Signal Transduction Events in the Generation of Aggressor CD4+T Cells in Herpetic Stromal Keratitis Pathogenesis. Journal of Interferon and Cytokine Research, 2007, 27, 65-75.	0.5	14
83	Innate Recognition Network Driving Herpes Simplex Virus-Induced Corneal Immunopathology: Role of the Toll Pathway in Early Inflammatory Events in Stromal Keratitis. Journal of Virology, 2007, 81, 11128-11138.	1.5	78
84	Regulatory T cells and immunity to pathogens. Expert Opinion on Biological Therapy, 2007, 7, 1301-1309.	1.4	19
85	Regulatory T cells in health and disease. Journal of Internal Medicine, 2007, 262, 78-95.	2.7	60
86	Quantitative analysis of herpes simplex virus type 1-specific memory B cells generated by different routes of infection. Virology, 2007, 360, 136-142.	1.1	6
87	Viruses and autoimmunity. Autoimmunity, 2006, 39, 71-77.	1.2	39
88	Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Experimental Eye Research, 2006, 82, 46-54.	1.2	89
89	Waking up T cells to counteract chronic infections. Trends in Immunology, 2006, 27, 205-207.	2.9	4
90	Regulatory T cells in virus infections. Immunological Reviews, 2006, 212, 272-286.	2.8	246

#	Article	lF	CITATIONS
91	Immunological Memory. Immunological Reviews, 2006, 211, 5-7.	2.8	19
92	Treg control of antimicrobial T cell responses. Current Opinion in Immunology, 2006, 18, 344-348.	2.4	55
93	A strategy for selective, CD4+ T cell-independent activation of virus-specific memory B cells for limiting dilution analysis. Journal of Immunological Methods, 2006, 313, 110-118.	0.6	9
94	A Tale of Two Â-Herpesviruses: Lessons for Vaccinologists. Clinical Infectious Diseases, 2006, 42, 810-817.	2.9	28
95	Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. Journal of Immunology, 2006, 177, 4122-4131.	0.4	17
96	Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation. Journal of Leukocyte Biology, 2006, 80, 1405-1415.	1.5	23
97	Application of FGF-2 to Modulate Herpetic Stromal Keratitis. Current Eye Research, 2006, 31, 1021-1028.	0.7	7
98	Qa-1b and CD94-NKG2a Interaction Regulate Cytolytic Activity of Herpes Simplex Virus-Specific Memory CD8+ T Cells in the Latently Infected Trigeminal Ganglia. Journal of Immunology, 2006, 176, 1703-1711.	0.4	66
99	Early events in HSV keratitisâ€"setting the stage for a blinding disease. Microbes and Infection, 2005, 7, 799-810.	1.0	169
100	Natural regulatory T cells in infectious disease. Nature Immunology, 2005, 6, 353-360.	7.0	914
101	Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology, 2005, 331, 151-158.	1.1	22
102	Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of Leukocyte Biology, 2005, 78, 178-186.	1.5	33
103	Application of Plasmid DNA Encoding IL-18 Diminishes Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. Journal of Immunology, 2005, 175, 509-516.	0.4	33
104	In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral Immunopathology. Journal of Virology, 2005, 79, 11935-11942.	1.5	66
105	Role of Inflammatory Cytokine-Induced Cycloxygenase 2 in the Ocular Immunopathologic Disease Herpetic Stromal Keratitis. Journal of Virology, 2005, 79, 10589-10600.	1.5	26
106	Regulation of Microbial Immunity: The Suppressor Cell Renaissance. Viral Immunology, 2005, 18, 411-418.	0.6	9
107	Blocking Mouse MMP-9 Production in Tumor Cells and Mouse Cornea by Short Hairpin (sh) RNA Encoding Plasmids. Oligonucleotides, 2005, 15, 72-84.	2.7	18
108	In vivo rescue of defective memory CD8 + T cells by cognate helper T cells. Journal of Leukocyte Biology, 2005, 78, 879-887.	1.5	16

#	Article	IF	Citations
109	Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. Journal of Leukocyte Biology, 2005, 77, 24-32.	1.5	45
110	Viruses and autoimmunity. Autoimmunity, 2005, 38, 559-565.	1.2	5
111	Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11462-11467.	3.3	80
112	A novel flow cytometry based assay for quantification of corneal angiogenesis in the mouse model of herpetic stromal keratitis. Experimental Eye Research, 2005, 80, 73-81.	1.2	5
113	Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with Herpes Simplex Virus. Vaccine, 2005, 23, 3526-3534.	1.7	29
114	Concomitant Helper Response Rescues Otherwise Low Avidity CD8+ Memory CTLs to Become Efficient Effectors In Vivo. Journal of Immunology, 2004, 172, 3719-3724.	0.4	26
115	Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. Journal of Leukocyte Biology, 2004, 76, 868-875.	1.5	29
116	Herpetic eye disease: immunopathogenesis and therapeutic measures. Expert Reviews in Molecular Medicine, 2004, 6, 1-14.	1.6	39
117	CXCR2â^'/â^'Mice Show Enhanced Susceptibility to Herpetic Stromal Keratitis: A Role for IL-6-Induced Neovascularization. Journal of Immunology, 2004, 172, 1237-1245.	0.4	79
118	CD4+CD25+ Regulatory T Cells Control the Severity of Viral Immunoinflammatory Lesions. Journal of Immunology, 2004, 172, 4123-4132.	0.4	310
119	Protective and Pathological Roles of Virus-Specific and Bystander CD8+T Cells in Herpetic Stromal Keratitis. Journal of Immunology, 2004, 173, 7575-7583.	0.4	41
120	Mice Transgenic for IL-1 Receptor Antagonist Protein Are Resistant to Herpetic Stromal Keratitis: Possible Role for IL-1 in Herpetic Stromal Keratitis Pathogenesis. Journal of Immunology, 2004, 172, 3736-3744.	0.4	61
121	Regulatory Cells and Infectious Agents: Deltentes Cordiale and Contraire. Journal of Immunology, 2004, 173, 2211-2215.	0.4	125
122	CD4 + CD25 + T Cells Regulate Vaccine-Generated Primary and Memory CD8 + T-Cell Responses against Herpes Simplex Virus Type 1. Journal of Virology, 2004, 78, 13082-13089.	1.5	139
123	Molecular adjuvants for mucosal immunity. Immunological Reviews, 2004, 199, 100-112.	2.8	61
124	Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes. American Journal of Pathology, 2004, 165, 2177-2185.	1.9	226
125	Influence of CCR7 ligand DNA preexposure on the magnitude and duration of immunity. Virology, 2003, 312, 169-180.	1.1	14
126	Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes and Infection, 2003, 5, 571-578.	1.0	41

#	Article	IF	CITATIONS
127	Toll-like receptor ligand links innate and adaptive immune responses by the production of heat-shock proteins. Journal of Leukocyte Biology, 2003, 73, 574-583.	1.5	27
128	CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses. Journal of Experimental Medicine, 2003, 198, 889-901.	4.2	478
129	Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1. Journal of Virology, 2003, 77, 12742-12752.	1.5	49
130	Antigenic peptides complexed to phylogenically diverse Hsp70s induce differential immune responses. Cell Stress and Chaperones, 2003, 8, 134.	1.2	12
131	DNA Vaccines Against Herpesviruses. , 2003, , 126-140.		0
132	DNA containing CpG motifs induces angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8944-8949.	3.3	88
133	Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes. Journal of Virology, 2002, 76, 6568-6576.	1.5	52
134	Immunization with Chaperone-Peptide Complex Induces Low-Avidity Cytotoxic T Lymphocytes Providing Transient Protection against Herpes Simplex Virus Infection. Journal of Virology, 2002, 76, 136-141.	1.5	40
135	Herpetic stromal keratitis in the absence of viral antigen recognition. Cellular Immunology, 2002, 219, 108-118.	1.4	39
136	Mechanisms of pathogenesis in herpetic immunoinflammatory ocular lesions. Veterinary Microbiology, 2002, 86, 17-26.	0.8	41
137	Viruses and autoimmunity: an affair but not a marriage contract. Reviews in Medical Virology, 2002, 12, 107-113.	3.9	31
138	Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. Journal of Clinical Investigation, 2002, 110, 1105-1111.	3.9	93
139	Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. Journal of Clinical Investigation, 2002, 110, 1105-1111.	3.9	86
140	DNA containing bioactive CpG motifs promote angiogenesis. Drug News and Perspectives, 2002, 15, 358.	1.9	7
141	IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis. Journal of Leukocyte Biology, 2002, 71, 469-76.	1.5	25
142	Control of Stromal Keratitis by Inhibition of Neovascularization. American Journal of Pathology, 2001, 159, 1021-1029.	1.9	94
143	Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine, 2001, 19, 4685-4693.	1.7	56
144	Induction of arginases I and II in cornea during herpes simplex virus infection. Virus Research, 2001, 73, 177-182.	1.1	30

#	Article	IF	CITATIONS
145	Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections. Expert Opinion on Biological Therapy, 2001, 1, 213-225.	1.4	12
146	Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis. Journal of Virology, 2001, 75, 9828-9835.	1.5	175
147	Lymphotoxin αâ^'/â^'Mice Develop Functionally Impaired CD8+T Cell Responses and Fail to Contain Virus Infection of the Central Nervous System. Journal of Immunology, 2001, 166, 1066-1074.	0.4	70
148	Bystander Activation Involving T Lymphocytes in Herpetic Stromal Keratitis. Journal of Immunology, 2001, 167, 2902-2910.	0.4	88
149	Herpes Simplex Virus-Induced Keratitis: Evaluation of the Role of Molecular Mimicry in Lesion Pathogenesis. Journal of Virology, 2001, 75, 3077-3088.	1.5	75
150	Modulation of Immunity against Herpes Simplex Virus Infection via Mucosal Genetic Transfer of Plasmid DNA Encoding Chemokines. Journal of Virology, 2001, 75, 569-578.	1.5	82
151	Plasmid DNA Encoding CCR7 Ligands Compensate for Dysfunctional CD8+ T Cell Responses by Effects on Dendritic Cells. Journal of Immunology, 2001, 167, 3592-3599.	0.4	21
152	Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules. Journal of Immunology, 2001, 166, 5473-5479.	0.4	102
153	Why do we lack an effective vaccine against herpes simplex virus infections?. Microbes and Infection, 2000, 2, 973-978.	1.0	31
154	Dual Role of B Cells in Mediating Innate and Acquired Immunity to Herpes Simplex Virus Infections. Cellular Immunology, 2000, 202, 79-87.	1.4	29
155	On the Mechanisms of T Cell Silencing by IL-10 DNA: Direct and Indirect Inhibition of T Cell Functions. Cellular Immunology, 2000, 206, 59-69.	1.4	2
156	Involvement of an ATP-Dependent Peptide Chaperone in Cross-Presentation After DNA Immunization. Journal of Immunology, 2000, 165, 750-759.	0.4	36
157	Application of the Intracellular Gamma Interferon Assay To Recalculate the Potency of CD8+ T-Cell Responses to Herpes Simplex Virus. Journal of Virology, 2000, 74, 5709-5711.	1.5	25
158	Pathogenesis of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions in B-Cell-Deficient Mice. Journal of Virology, 2000, 74, 3517-3524.	1.5	34
159	Resistance to Herpetic Stromal Keratitis in Immunized B-Cell-Deficient Mice. Virology, 1999, 257, 168-176.	1.1	18
160	Immune Modulation by IL-10 Gene Transfer via Viral Vector and Plasmid DNA: Implication for Gene Therapy. Cellular Immunology, 1999, 194, 194-204.	1.4	30
161	Bystander activation of CD4+ T cells can represent an exclusive means of immunopathology in a virus infection. European Journal of Immunology, 1999, 29, 3674-3682.	1.6	64
162	Host-microbe interactions: fungi/viruses/parasites. Current Opinion in Microbiology, 1999, 2, 343-347.	2.3	1

#	Article	IF	CITATIONS
163	Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. Journal of NeuroVirology, 1999, 5, 42-47.	1.0	35
164	Immune Responsiveness of Lymphotoxin-α-Deficient Mice: Two Reconstitution Models. Cellular Immunology, 1998, 189, 116-124.	1.4	8
165	Control of Herpetic Stromal Keratitis Using CTLA4lg Fusion Protein. Clinical Immunology and Immunopathology, 1998, 86, 88-94.	2.1	25
166	Modulation of Mucosal and Systemic Immunity by Enteric Administration of Nonreplicating Herpes Simplex Virus Expressing Cytokines. Virology, 1998, 240, 245-253.	1.1	31
167	Protection by minigenes: a novel approach of DNA vaccines. Vaccine, 1998, 16, 1660-1667.	1.7	24
168	Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine, 1998, 16, 1103-1110.	1.7	51
169	Herpes simplex virus latency and the immune response. Current Opinion in Microbiology, 1998, 1, 430-435.	2.3	59
170	DNA vaccines for the prophylaxis and modulation of HSV infections. Expert Opinion on Investigational Drugs, 1998, 7, 219-224.	1.9	4
171	Production of Key Molecules by Ocular Neutrophils Early After Herpetic Infection of the Cornea. Experimental Eye Research, 1998, 67, 619-624.	1.2	86
172	Herpes Simplex Virus Replication-Induced Expression of Chemokines and Proinflammatory Cytokines in the Eye: Implications in Herpetic Stromal Keratitis. Journal of Interferon and Cytokine Research, 1998, 18, 681-690.	0.5	79
173	Modulation of Viral Immunoinflammatory Responses with Cytokine DNA Administered by Different Routes. Journal of Virology, 1998, 72, 5545-5551.	1.5	32
174	Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. Journal of Leukocyte Biology, 1997, 61, 125-132.	1.5	121
175	Immunopathogenesis of herpetic ocular disease. Immunologic Research, 1997, 16, 375-386.	1.3	103
176	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. International Journal of Cancer, 1997, 70, 706-718.	2.3	178
177	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts., 1997, 70, 706.		2
178	DNA Vaccines â° A Modern Gimmick or a Boon to Vaccinology?. Critical Reviews in Immunology, 1997, 17, 139-154.	1.0	100
179	Role of interferon-Î ³ in immunity to herpes simplex virus. Journal of Leukocyte Biology, 1996, 60, 528-532.	1.5	58
180	Herpesvirus vaccines. Advanced Drug Delivery Reviews, 1996, 21, 63-76.	6.6	3

#	Article	IF	Citations
181	The Role of the Innate Immune System in the Reconstituted SCID Mouse Model of Herpetic Stromal Keratitis. Clinical Immunology and Immunopathology, 1996, 80, 23-30.	2.1	35
182	HSV-1-Mediated Modulation of Cytokine Gene Expression in a Permissive Cell Line: Selective Upregulation of IL-6 Gene Expression. Virology, 1996, 219, 295-300.	1.1	55
183	Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. European Journal of Immunology, 1996, 26, 161-165.	1.6	118
184	Virus-Induced Immunopathology. Advances in Virus Research, 1996, 47, 353-376.	0.9	34
185	Virus-Induced Immunosuppression. , 1996, , 131-156.		1
186	Induction of Protective Immunity against Herpes Simplex Virus with DNA Encoding the Immediate Early Protein ICP 27. Viral Immunology, 1995, 8, 53-61.	0.6	67
187	Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. International Immunology, 1995, 7, 679-688.	1.8	90
188	Vaccination with the Immediate-Early Protein ICP47 of Herpes Simplex Virus-Type 1 (HSV-1) Induces Virus-Specific Lymphoproliferation, but Fails to Protect against Lethal Challenge. Virology, 1994, 200, 236-245.	1.1	26
189	Quantitative studies on CD4+ and CD8+ cytotoxic T lymphocyte responses against herpes simplex virus type 1 in normal and \hat{l}^2 2-m deficient mice. Immunobiology, 1994, 190, 183-194.	0.8	16
190	Dysregulation of cytokine expression in monocytes from HIV-positive individuals. Journal of Leukocyte Biology, 1994, 56, 347-352.	1.5	13
191	Limitations and modifications of quantitative polymerase chain reaction. Journal of Immunological Methods, 1993, 165, 207-216.	0.6	64
192	The Proportion of Herpes Simplex Virus-Specific Cytotoxic T Lymphocytes (Tc) That Recognize Glycoprotein C Varies between Individual Mice and Is Dependent on the Form of Immunization. Viral Immunology, 1993, 6, 21-33.	0.6	7
193	Efficacy of the Herpes Simplex Virus Types 1 and 2 Mutant Viruses to Confer Protection against Zosteriform Spread in Mice. Viral Immunology, 1993, 6, 35-42.	0.6	6
194	Use of quantitative polymerase chain reaction to quantitate cytokine messenger RNA molecules. Molecular Immunology, 1992, 29, 1229-1236.	1.0	48
195	Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. Journal of Immunological Methods, 1992, 152, 237-243.	0.6	39
196	MHC II-restricted, CD4+ cytotoxic T lymphocytes specific for herpes simplex virus-1: Implications for the development of herpetic stromal keratitis in mice. Clinical Immunology and Immunopathology, 1991, 61, 398-409.	2.1	30
197	pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. Journal of Immunological Methods, 1991, 141, 157-163.	0.6	108
198	An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. Journal of Immunological Methods, 1991, 145, 143-152.	0.6	32

#	Article	IF	Citations
199	The Mouse Model and Understanding Immunity to Herpes Simplex Virus. Clinical Infectious Diseases, 1991, 13, S935-S945.	2.9	60
200	Apparent Requirement for CD4 ⁺ T Cells in Primary Anti-Herpes Simplex Virus Cytotoxic T-Lymphocyte Induction Can Be Overcome by Optimal Antigen Presentation. Viral Immunology, 1991, 4, 177-186.	0.6	22
201	Role of Coexpression of IL-2 and Herpes Simplex Virus Proteins in Recombinant Vaccinia Virus Vectors on Levels of Induced Immunity. Viral Immunology, 1990, 3, 207-215.	0.6	20
202	The Control of Human Herpesvirus Infections by Cytotoxic T Lymphocytes(CTL): A Comparison to AIDS Virus Specific CTL., 1990,, 73-98.		3
203	Antiviral Cytotoxic T-Lymphocytes and Vaccines. , 1989, , 239-266.		0
204	Cytotoxic T Lymphocytes Annals of the New York Academy of Sciences, 1988, 532, 257-272.	1.8	40
205	Functional T Cell Recognition of Synthetic Peptides Corresponding to Continuous Antibody Epitopes of Herpes Simplex Virus Type 1 Glycoprotein D. Immunobiology, 1988, 177, 134-148.	0.8	18
206	Virus-Induced Immunosuppression. Veterinary Clinics of North America - Small Animal Practice, 1986, 16, 1097-1127.	0.5	5
207	Interferon Produced Endogenously in Response to CSF-1 Augments the Functional Differentiation of Progeny Macrophages. Journal of Leukocyte Biology, 1985, 37, 659-664.	1.5	31
208	Immunopathology of Herpesvirus Infections. , 1985, , 103-119.		10
209	Cytotoxic T lymphocytes in herpesvirus infections. Veterinary Immunology and Immunopathology, 1984, 6, 35-66.	0.5	24
210	Frequency of Cytotoxic T Lymphocyte Precursors to Herpes Simplex Virus Type 1 as Determined by Limiting Dilution Analysis. Infection and Immunity, 1983, 39, 785-792.	1.0	23
211	Role of Ia Antigen Expression and Secretory Function of Accessory Cells in the Induction of Cytotoxic T Lymphocyte Responses Against Herpes Simplex Virus. Infection and Immunity, 1982, 37, 1138-1147.	1.0	15
212	Neutrophils in Antiviral Immunity: Inhibition of Virus Replication by a Mediator Produced by Bovine Neutrophils. Journal of Infectious Diseases, 1980, 141, 223-232.	1.9	43
213	Mechanisms of Viral Immunopathology. Advances in Veterinary Medicine, 1979, 23, 103-136.	0.1	8
214	Human neutrophil – mediated destruction of antibody sensitized herpes simplex virus type I infected cells. Canadian Journal of Microbiology, 1978, 24, 182-186.	0.8	28
215	Characterization of Surface Receptors on Bovine Leukocytes. International Archives of Allergy and Immunology, 1978, 56, 289-300.	0.9	47
216	Interactions between Effector Cell Activity and Lymphokines: Implications for Recovery from Herpesvirus Infections. International Archives of Allergy and Immunology, 1978, 57, 62-73.	0.9	22

#	Article	IF	CITATIONS
217	The effect of the antiherpesvirus drug 5-methoxymethyl- $2\hat{a}\in \mathbb{C}^2$ -deoxyuridine on the humoral immune response in vivo. Canadian Journal of Microbiology, 1977, 23, 1059-1061.	0.8	6
218	Bovine Type II Interferon: Activity in Heterologous Cells. Intervirology, 1977, 8, 250-256.	1.2	26
219	Complement enhances antiviral antibody-dependent cell cytotoxicity. Nature, 1977, 266, 456-458.	13.7	36
220	Polymorph-mediated antibody-dependent cytotoxicity—modulation of activity by drugs and immune interferon. Canadian Journal of Microbiology, 1976, 22, 1222-1228.	0.8	24
221	The role of antibody dependent cytotoxicity in recovery from herpesvirus infections. Cellular Immunology, 1976, 22, 182-186.	1.4	56
222	Lymphocyte Activation by Cell Separation Procedures. Immunological Investigations, 1976, 5, 637-648.	0.9	14
223	Comparison of the Antiviral Effects of 5-Methoxymethyl-deoxyuridine with 5-lododeoxyuridine, Cytosine Arabinoside, and Adenine Arabinoside. Antimicrobial Agents and Chemotherapy, 1975, 8, 643-650.	1.4	50
224	Host defense mechanisms against infectious bovine rhinotracheitis virus. Cellular Immunology, 1975, 17, 43-56.	1.4	51
225	Host Defense Mechanisms Against Infectious Bovine Rhinotracheitis Virus: In Vitro Stimulation of Sensitized Lymphocytes by Virus Antigen. Infection and Immunity, 1974, 10, 681-687.	1.0	90
226	Depression of Humoral Antibody Formation in the Chicken by Thymectomy and Antilymphocyte Serum. Nature: New Biology, 1972, 236, 79-80.	4.5	16
227	EQUINE INFLUENZA IMMUNISATION—THE ROLE OF NASAL ANTIBODY—A REVIEW. Australian Veterinary Journal, 1971, 47, 146-148.	0.5	8
228	HSV: immunopathological aspects of HSV infection. , 0, , 642-655.		5
229	Regulation of Antimicrobial Immunity. , 0, , 109-120.		1
230	Immune Responses to Persistent Viruses. , 0, , 255-267.		0
231	Pathology and Pathogenesis of Virus Infections. , 0, , 383-389.		0
232	Acquired Immunity against Virus Infections. , 0, , 237-254.		1
233	Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy- <scp>d</scp> -Glucose with Metformin. Journal of Virology, 0, , .	1.5	5